IMO Health company overview
About
Expert Vetted Data
Public disclosures rarely capture a company's internal dynamics or the true state of its technology. Gain first-hand insight by speaking with former IMO Health executives.
Ownership & Key Financials
Revenue
Investors
Revenue / FTE
Ownership
FTEs
Products & Services
Clinical interface terminology and data quality management
Description: Core solutions providing clinical interface terminology and data quality management services to standardize medical terminology and impro•• •••••••• •••• ••••••••.••••: ••• ••••, ••• ••••••••• •••••••••, ••• ••••••••• ••••••• ••••: •••• •• •••••••••• ••••••••• ••• ••• ••••••• •• ••••••••••• •••••••• •••••••••••••, ••••••• ••••••• •••• ••••••••••, ••••••• •••••• ••••••••, ••• ••••••• •••••••••••••••• ••••••••••••.••• ••••••••: •••••••• ••••••••• ••••••••••• ••••••••, •••• ••••••••••••• ••••••, ••••• ••• •••••••••• ••••••••, ••••••• ••••••••• ••• •••••••••• ••••, •••••••• •••••••••• ••• •• •••••••••• •••••
Cloud-based platforms and data analytics
Description: Cloud-based solutions and data analytics platforms that leverage AI and NLP capabilities to extract insights from clinical data and suppo•• •••••••• •••••••••• •••••••••.••••: ••• ••••••, ••• ••••••'• •••, ••• •••••••• ••••• ••••: •••• •• ••••• •••••••• •••••••••••••, •••• •••••••• •••••••••, ••• •••••• •••• ••••• ••• •••••••• •• ••••••••••••, •••••••••• •••••• ••••••••••, •••••••• ••••• ••••••••••••, ••• •••••••• •••• •••••••••.••• ••••••••: ••••••-•••••••• •••••••• •• ••••••, ••••••••••• ••••••••••• ••• ••••••••••, ••••• •••••••• ••••• ••••• •• •••••••• ••••, ••••••• •• ••• •••••••• •••••••••••••, •••••••• •••••••• •••••••
Pricing & Go-to-market
Typical Contract Length
•-• ••••• •••• ••••••••• ••••••• (•••-•••)
Pricing model
Primarily subscription-based licensing with module-based pricing for terminology, normalization, and AI components. Pricing is driven by user or organ•••••••-••••• •••••••, •••• •••••••• •••••• ••••••• ••••••••••••• ••••• •• •••••••••• •••••••• •••• ••• ••• •••••• ••••••••••••.
Average Sales Value
$••,••• •• •••• $•• ••• •••• •••••••••; •••••-••••• ••••••••• ••••••••• $••,••• •• $•••,••• •• ••••••, ••••••••• •• •••••••••••• •••• ••• •••••
Average Sales Cycle
••-•• ••••••
Growth Review
| Company Name | Revenue | FTE | Proprietary Insights | HQ | Ownership Type |
|---|---|---|---|---|---|
 IMO Health | - | ••• '•• | - | USA | P•••••••• |
| S Spheris | - | - | - | - | - |
| S Spheris | - | - | - | - | - |
 Clinical Architecture | - | - | - | - | F•••••••••••• |
| Clinical Architecture | - | - | - | - | F•••••••••••• |
 Apelon | - | - | - | - | F•••••••••••• |
| Apelon | - | - | - | - | F•••••••••••• |
Experts highlight IMO Health's operational execution and market approach, while noting market evolution and timing considerations as a potential constraint.
What does Origin provide on IMO Health?
Origin provides a structured company snapshot of IMO Health, combining expert-led insights with analysis across business model, customers, competitors, and market dynamics. The profile is designed to support research, competitive analysis, and commercial due diligence workflows.
How is Origin's analysis of IMO Health different from traditional company databases?
Traditional company databases often focus on surface-level metadata such as ownership, funding, and company descriptions. Origin complements these sources with qualitative insights informed by expert interviews, helping teams understand how IMO Health operates, competes, and creates value in practice.
Is Origin suitable for researching private companies like IMO Health?
Yes. Origin is built to support research on private companies, where public information can be limited or inconsistent. It focuses on insight depth and operational context, which can be useful when evaluating companies like IMO Health for investment, partnership, or competitive analysis.
Where does Origin's information on IMO Health come from?
Origin insights are derived from expert interviews conducted by Dialectica, combined with structured analysis and secondary validation where appropriate. This approach prioritises first-hand operational perspectives alongside supporting evidence, rather than relying solely on aggregated public data.
Can Origin support commercial due diligence on IMO Health?
Origin can support early-stage commercial due diligence by helping teams quickly understand positioning, value drivers, customer dynamics, and potential risks related to IMO Health. It is typically used to shape hypotheses and focus areas before deeper primary research.
How does Origin compare to Crunchbase or PitchBook for analysing IMO Health?
Crunchbase and PitchBook primarily focus on company metadata, ownership, funding history, and transactions. Origin complements those sources by adding qualitative, insight-led analysis focused on business fundamentals, go-to-market execution, customer reality, and competitive positioning for companies like IMO Health.
How can Origin support portfolio monitoring or add-on analysis for companies like IMO Health?
For PE-backed contexts, Origin can support monitoring by surfacing changes in competitive intensity, customer demand signals, and go-to-market effectiveness. It can also inform add-on analysis by clarifying adjacency opportunities and how a target like IMO Health may fit within a broader platform strategy.
What does Origin typically reveal about pricing and go-to-market strategy for enterprise software companies like IMO Health?
For enterprise software, Origin often focuses on pricing logic, contract structure, buyer personas, procurement friction, and channel strategy. For companies like IMO Health, this can help teams assess how revenue is created, what drives expansion, and where sales cycles or retention may impact outcomes.
Relevant Companies
FinThrive
Revenue cycle management software platform for healthcare organizations to manage patient access, charge integrity, claims, contracts, and revenue recovery with integrated AI, automation, and analytics tools.
HQ
Ownership
Investors
Aetion
Real-world evidence analytics platform for biopharmaceutical companies, payers, and regulators to generate evidence on treatment safety, effectiveness, and value.